Stan Berenshteyn
Stock Analyst at Wells Fargo
(0.99)
# 3,835
Out of 5,182 analysts
86
Total ratings
31.37%
Success rate
-17.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHR Phreesia | Maintains: Overweight | $30 → $25 | $8.56 | +192.06% | 2 | Mar 26, 2026 | |
| CTEV Claritev | Maintains: Equal-Weight | $30 → $22 | $17.37 | +26.66% | 3 | Mar 19, 2026 | |
| HCAT Health Catalyst | Downgrades: Equal-Weight | $5 → $1 | $1.06 | -5.66% | 8 | Mar 18, 2026 | |
| VEEV Veeva Systems | Maintains: Overweight | $333 → $317 | $158.45 | +100.06% | 10 | Mar 5, 2026 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $7 → $3.5 | $2.15 | +62.79% | 9 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $8 → $6 | $5.22 | +14.94% | 4 | Feb 26, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $41 → $36 | $22.16 | +62.45% | 2 | Feb 19, 2026 | |
| DOCS Doximity | Maintains: Overweight | $55 → $45 | $22.66 | +98.59% | 14 | Feb 6, 2026 | |
| HNGE Hinge Health | Initiates: Overweight | $68 | $37.83 | +79.75% | 1 | Jan 9, 2026 | |
| OMDA Omada Health | Initiates: Equal-Weight | $17 | $12.13 | +40.15% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $52 | $35.00 | +48.57% | 18 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $5.55 | +62.16% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $125 | $79.91 | +56.43% | 9 | Feb 26, 2025 |
Phreesia
Mar 26, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $8.56
Upside: +192.06%
Claritev
Mar 19, 2026
Maintains: Equal-Weight
Price Target: $30 → $22
Current: $17.37
Upside: +26.66%
Health Catalyst
Mar 18, 2026
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $1.06
Upside: -5.66%
Veeva Systems
Mar 5, 2026
Maintains: Overweight
Price Target: $333 → $317
Current: $158.45
Upside: +100.06%
GoodRx Holdings
Mar 4, 2026
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.15
Upside: +62.79%
Teladoc Health
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $5.22
Upside: +14.94%
Waystar Holding
Feb 19, 2026
Maintains: Overweight
Price Target: $41 → $36
Current: $22.16
Upside: +62.45%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $55 → $45
Current: $22.66
Upside: +98.59%
Hinge Health
Jan 9, 2026
Initiates: Overweight
Price Target: $68
Current: $37.83
Upside: +79.75%
Omada Health
Jan 9, 2026
Initiates: Equal-Weight
Price Target: $17
Current: $12.13
Upside: +40.15%
Jan 5, 2026
Maintains: Overweight
Price Target: $43 → $52
Current: $35.00
Upside: +48.57%
Nov 5, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $5.55
Upside: +62.16%
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $79.91
Upside: +56.43%